---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002220"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-04-25T23:59:59+00:00"
generated_at: "2026-06-03T08:07:30.472084+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# FDA grants Fast Track Designation for Compass's CTX-009 in biliary tract cancer

## Summary
- FDA Fast Track Designation for CTX-009 (bispecific DLL4/VEGF-A antibody) + paclitaxel in previously treated metastatic/locally advanced biliary tract cancer.
- Phase 2 data showed ORR 37.5% (9/24), median PFS 9.4 months, median OS 12.5 months.
- Enrollment in Phase 2/3 COMPANION-002 study expected to complete mid-2024; top-line data by year-end 2024.
- Co-founder Thomas Schuetz highlighted large unmet need with current single-digit response rates.

## SEC filing metadata
- accession: 0001171843-24-002220
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-04-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/0001171843-24-002220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324002220/f8k_042424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002220
- JSON: https://secwatch.observer/filing/0001171843-24-002220.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.